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Protein kinase G (PknG) is a eukaryotic-like serine/threonine kinase that is expressed
by Mycobacterium tuberculosis and promotes survival of mycobacteria in host
macrophages by suppressing phagosome-lysosome fusion. Thus, compounds showing
inhibitory activity against PknG are promising anti-mycobacterial agents. We therefore
aimed to develop anti-mycobacterial agents by identifying new PknG inhibitors.
A luciferase-based PknG kinase assay was used to screen potential inhibitors of
PknG. We found that four compounds, namely AZD7762, R406, R406-free base, and
CYC116, inhibited PknG activities. AZD7762, R406, and R406-free base promoted
transfer of mycobacteria to lysosomes. These compounds also inhibited survival of
M. bovis Bacillus Calmette–Guérin (BCG) inside human macrophages. Furthermore,
R406 and R406-free base showed bactericidal activity against BCG in infected human
macrophages without cytotoxicity. The PknG inhibitors identified in this study by the
luciferase-based PknG kinase assay may be promising leads for the development of
anti-mycobacterial agents.
Keywords: eukaryotic-like serine/threonine kinase, PknG, macrophages, phagolysosome, anti-mycobacterial,
chemotherapy
INTRODUCTION
Tuberculosis (TB) is one of the most important global health problems, with about 10 million new
cases arising every year (Zumla et al., 2015). The virulence of Mycobacterium tuberculosis is linked
to its capacity to survive within macrophages that are designed to destroy phagocytosed pathogens
(Frieden et al., 2003). While in healthy persons, a functional immune system keeps intracellular
bacteria in check, if the immune system of infected persons is impaired by, for example, infection
with the human immunodeficiency virus or the administration of anti-inflammatory drugs or
immunosuppressants, M. tuberculosis can rapidly spread and cause disease (Frieden et al., 2003).
An additional problem is that strains resistant against current drugs are spreading globally
(Matteelli et al., 2014), and therefore it is important to develop anti-TB agents that can efficiently
target M. tuberculosis.
Mycobacterium spp., such as M. tuberculosis and M. bovis Bacillus Calmette–Guérin (BCG),
survive and persistently infect in macrophages by escaping from the host lysosomal degradation
pathway (Armstrong and Hart, 1975). A eukaryotic-like serine/threonine kinase, protein kinase
G (PknG), was shown to play a pivotal role in blocking phagosome-lysosome fusion within
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infected macrophages (Walburger et al., 2004). Mycobacteria
that are deficient in PknG are predominantly found within
lysosomes compared with wild-type mycobacteria that reside
in phagosomes (Walburger et al., 2004). In addition, when
severe combined immunodeficiency mice are infected with
M. tuberculosis, the mice infected with PknG-deficient bacteria
are able to survive longer than those infected with wild-type
bacteria (Cowley et al., 2004; Sundaramurthy et al., 2017),
suggesting that suppression of phagosome-lysosome fusion by
PknG allows mycobacteria to escape from lysosomal degradation
and to grow within macrophages. Blocking PknG by use of
the specific PknG kinase inhibitor AX20017, which targets
the ATP binding site of the PknG kinase domain, resulted
in the effective lysosomal delivery and death of internalized
mycobacteria (Walburger et al., 2004; Scherr et al., 2007).
PknG-inhibiting compounds discovered from flavonoids and
aminopyrimidine derivatives were considered promising anti-
mycobacterials (Anand et al., 2012).
It is important to increase the number of lead compounds that
inhibit PknG activity. Additional PknG inhibitors were screened
by measuring ATP consumption, based on kinase activity that
transfers phosphate groups from ATP to substrates (Baki et al.,
2007). The radiometric-based kinase assay for screening PknG
inhibitors measured the incorporation of radioactive phosphate
into myelin basic protein (MBP) (Koul et al., 2001). In this assay,
MBP was incubated with γ33P-labeled ATP in the presence of
PknG. We here present a luciferase-based PknG kinase assay
that was used to search for PknG inhibitors that can effectively
suppress intracellular mycobacterial growth.
MATERIALS AND METHODS
Cell Lines and Bacterial Strains
THP-1 and J774.1 cell lines were cultured with RPMI 1640
medium (Sigma-Aldrich, St. Louis, MO, United States)
supplemented with 10% fetal calf serum. The THP-1 cells
were differentiated by stimulation with 50 nM phorbol 12-
myristate 13-acetate (Sigma-Aldrich) for 2 days. M. bovis strain
BCG-Tokyo 172 (BCG) was purchased from ATCC (Manassas,
VA, United States). Green fluorescent protein (GFP)-expressing
BCG (WT BCG) and PknG knockout BCG-GFP (1PknG
BCG) were also used (Walburger et al., 2004). BCG was
propagated in 7H9 mycobacterial medium (BD, Franklin Lakes,
NJ, United States) supplemented with 10% Middlebrook ADC
Growth Supplement (Sigma-Aldrich) and 0.05% Tween80 or
7H11 mycobacterial medium (BD) supplemented with 10%
Middlebrook OADC Growth Supplement (Sigma-Aldrich) and
0.05% Tween80. The bacterial suspension was gently sonicated
using a sonicator (UR-20P, Tomy, Tokyo, Japan) for 5 s and
centrifuged at 150 × g for 5 min to eliminate bacterial clumps
and was then used.
The protocols related to biosafety issues were approved by the
institutional review board of the Shimane University. Each study
was conducted under the rules for preventing dispersal of living
modified organism. The living modified organisms were handled
inside a biosafety cabinet at a level 2 or level 3 facility.
GST-PknG Fusion Protein Purification
The pknG gene was amplified by PCR using KOD-Plus
polymerase (Toyobo, Osaka, Japan) from M. tuberculosis
H37Ra (ATCC 25177) genomic DNA using specific primers
(FW: 5′-GGCCAAGCGTCAGAGACCGAACGTTCGGG-3′,
RV: 5′-TTAGAACGTGCTGGTGGGCCGGACCTTG-3′). For
the thermal cycling, initial denaturation at 94◦C for 3 min was
followed by 35 cycles of denaturation at 94◦C for 30 s, annealing
at 55◦C for 30 s, and extension at 68◦C for 3 min. Amplified
pknG gene was inserted into pGEX-3X vector (GE Healthcare,
Little Chalfont, United Kingdom) to create a GST-pknG fusion
gene (Smith and Johnson, 1988), which was expressed in E. coli
strain BL21 (GE Healthcare) and induced by 0.1 mM IPTG
treatment at 25◦C.
Bacterial cell pellets were suspended with cold phosphate
buffered saline (PBS), disrupted by sonication (ON: 30 s/OFF:
30 s × 10) (Bioruptor, UCD-200, Cosmo Bio, Tokyo, Japan) and
then dissolved with 1% Triton-X100. The mixture was clarified
by a 5 min centrifugation at 13,400 × g. The supernatant was
mixed with glutathione-sepharose 4B (GE Healthcare) beads and
incubated for 30 min at 4◦C. The beads were washed five times
with cold PBS by centrifugation (2,300 × g, 5 min). The washed
beads were then suspended with lysis buffer (20 mM reduced
glutathione, 50 mM Tris–HCl, pH 8.0) and incubated for 5 min
on ice. Supernatants obtained by centrifugation at 2,300 × g
for 5 min were subjected to SDS–PAGE to verify the purified
GST-PknG.
Luciferase-Based PknG Kinase Assay
A luciferase-based PknG kinase assay was established with
minor modification from the previously reported method (Baki
et al., 2007). The test compounds dissolved with dimethyl
sulfoxide (DMSO) were diluted with double-distilled H2O. The
reagents composed of 20 µL of mixture (10 µM test compound,
1 µM GST-PknG, and 20 µL of kinase reaction buffer [5 µM
MBP (Funakoshi, Tokyo, Japan), 50 mM Tris–HCl (pH 7.6),
1 µM ATP, 1 mM dithiothreitol, 10 mM MnCl2, 250 µg/mL
bovine serum albumin]) were added in a white 96-well plate
(Thermo Fisher Scientific, Waltham, MA, United States). The
mixtures were incubated in the modified kinase reaction buffer
(Koul et al., 2001) at 30◦C for 30 min and then mixed
with 40 µL of Kinase-Glo reagent (Promega, Madison, WI,
United States). After incubating at room temperature for
10 min, the luminescence signal was measured by a DTX-
880 multi-mode plate reader (Beckman Coulter, Brea, CA,
United States).
We used 1 µM of ATP to screen the PknG inhibitors.
The level of ATP used was 1,000-fold lower than the level of
the intracellular ATP (Beis and Newsholme, 1975). However,
the linear relationship between the concentration of ATP and the
intensity of the luminescent signal could be observed in the ATP
concentrations between 0.1 and 16 µM, which was similar to the
original assay (Baki et al., 2007).
Kinase Inhibitors
AZD7762 (3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-
piperidin-3-yl] thiophene-2-carboxamide) is a checkpoint
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kinase (Chk) 1/2 inhibitor and exhibits anti-tumor activity by
inducing cell cycle arrest (Zabludoff et al., 2008). R406 ((6-
[[5-fluoro-2-[(3,4,5-trimethoxyphenyl) amino]-4-pyrimidinyl]
amino]-2,2-dimethyl-2H-pyrido[3,2-b]-1,4-oxazin-3(4H)-one))
and R406-free base (R406f) are human spleen tyrosine kinase
(Syk) inhibitors and used as lead compounds of drugs for
rheumatoid arthritis (Braselmann et al., 2006). CYC116 (4-
methyl-5-[2-(4-morpholinophenylamino) pyrimidin-4-yl]
thiazol-2-amine) is an Aurora kinase A/B inhibitor and shows
anti-tumor activity by repression of cell division (Wang et al.,
2010). These inhibitors were purchased from Sigma-Aldrich.
These inhibitors were dissolved with DMSO and further diluted
with each buffer or medium.
Quantitative Inhibitory Assay for
Inhibitors Against PknG Kinase
The luciferase-based PknG kinase inhibitory assay was performed
using a kinase inhibitor library (Kinase inhibitor library I,
Sigma-Aldrich) and PknG inhibitor (AX20017, Merck Millipore,
Billerica, MA, United States). The inhibition rate of kinase
activity by various compounds (%) was calculated as follows:
Inhibition (%) = 100 × [relative light intensity units (RLU)
raw data of sample – RLU positive control] / (RLU negative
control – RLU positive control). All data were plotted in terms
of an inhibition rate of AX20017 equal to 100%.
The half-maximal inhibitory concentration (IC50) was
calculated from the sigmoidal curve for the GST-PknG kinase
inhibition rate. The RLU values of GST-PknG and DMSO alone
were used as a positive and a negative control, respectively.
Direct Bactericidal Assay by
Mycobacterial Growth
Bacillus Calmette–Guérin at 1 × 105 colony forming units
(CFUs)/well was incubated with 10 µM of kinase inhibitors at
37◦C for 24 h. The bacterial suspension was diluted serially in
7H9 medium with 10% Middlebrook ADC Growth Supplement
and 0.05% Tween 80. A total of 10 µl of each diluent were plated
onto 7H11 agar plates containing 10% Middlebrook OADC
Growth Supplement and 0.05% Tween 80. The plates were
cultured for 3–4 weeks at 37◦C and CFUs were counted.
The ability of the compounds to inhibit bacterial growth
was assayed using alamarBlue cell viability reagent (Thermo
Fisher Scientific) to measure the reducing viability of bacteria.
Mycobacteria adjusted to an OD600 of 0.05 were incubated
with 7H9 medium containing 10% OADC and fourfold
serial dilutions (from 128 to 0.03 µM) of kinase inhibitors
for 6 days at 37◦C. Rifampicin was used as a control to
show inhibition. After incubation, 20 µL of alamarBlue cell
viability reagent was added to the bacterial suspension and
incubated for 4 h at 37◦C. The fluorescent signal (excitation:
535 nm/emission: 595 nm) was measured by a DTX-880 plate
reader.
Immunostaining
J774.1 cells on culture slides were infected with bacteria at a
multiplicity of infection (MOI) of 10 for 30 min and then
incubated with 10 µM of inhibitors for 90 min. Cells fixed with
methanol for 4 min at −20◦C were stained with Alexa Fluor
594 conjugated antibody against CD107a, known as lysosomal-
associated membrane protein-1 (LAMP1) (Cosmo Bio), for
45 min at room temperature (Chen et al., 1985). Slides were
observed using an FV1000-D laser scanning confocal microscope
(Olympus, Tokyo, Japan). One hundred randomized events were
analyzed for each drug, which were repeated three times and
statistically analyzed. The rate of lysosomal transfer (%) was
calculated as follows: lysosomal transfer (%) = 100 × (number
of bacteria overlapping LAMP-1 / total number of analyzed
bacteria.)
Phagocytosis Assay
Phagocytosis assay was performed as previously reported with
some modifications (Daigneault et al., 2010). J774.1 or THP-1
macrophages were seeded at 1.0× 105 cells into each well of a 96-
well plate and incubated with fourfold serial dilutions of kinase
inhibitors (from 128 to 0.03 µM) for 2 h at 37◦C. Then, red
fluorescent latex beads with a mean diameter of 2 µm (L3030;
Sigma-Aldrich) were opsonized by 10% human serum (Cosmo
Bio) for 30 min at 37◦C. The opsonized beads were added to
cells at an MOI of 10. The cells were then incubated for 2 h with
different concentrations of inhibitors. Cells were washed twice
with PBS, and red fluorescence (excitation, 535 nm/emission,
595 nm) was analyzed by a FACS Calibur flow cytometer
(BD). We used 10 µM of cytochalasin D (Sigma-Aldrich) as a
control, which completely inhibits actin polymerization (Cooper,
1987).
The fluorescence was compared with controls in 5,000 events.
The phagocytosis rate (%) was calculated according to the
following formula: phagocytosis (%) = 100 × [fluorescent cells
(sample—negative control) / fluorescent cells (positive control –
negative control)]. Positive and negative controls were the
addition of fluorescent beads and DMSO alone, respectively.
MTT Assay
To measure the cytotoxic effects of the kinase inhibitors, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
was used, because mitochondrial succinate dehydrogenase in
living cells reduces MTT to form insoluble formazan products
(Mosmann, 1983). Cells were seeded at 1.0 × 105 cells to each
well of a 96-well plate and incubated with serial concentrations
of kinase inhibitors for 24 h at 37◦C. A total of 20 µl of MTT
reagent adjusted to 5 µg/mL was added to each well. The plate
was shaken for 10 min and incubated in a dark condition for
1 h at 37◦C. Excess dye was removed and 200 µL of DMSO was
added to the plate. An absorbance of 550 nm was measured by a
DTX-880 plate reader.
Staurosporine was used as a control drug showing cytotoxicity,
because the drug is a potent, cell permeable protein kinase C
inhibitor and induces cell apoptosis (Couldwell et al., 1994).
The cell survival rate (%) was calculated by the formula: cell
survival (%) = 100 × [(absorbance of kinase inhibitors treated
cells – absorbance of solvent) / (absorbance of DMSO treated
cells – absorbance of solvent)].
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Mycobacterial Survival Assay
Differentiated THP-1 cells were infected with BCG at an MOI
of 10 for 2 h and then incubated with 10 µM of each inhibitor
for an additional 2 h (Chaurasiya and Srivastava, 2009). Infected
macrophages were washed once with PBS and incubated with
amikacin (20 µM) and each inhibitor (10 µM) for 24 h
at 37◦C. Macrophages were washed three times with warm
media and lysed with 200 µL of 0.05% SDS solution. The
reducing activity of bacteria was measured by alamarBlue cell
viability assay. The lysate was mixed with 20 µL of alamarBlue
cell viability reagent and incubated for 12 h at 37◦C. The
fluorescent signal was measured by a DTX-880 plate reader
(excitation: 535 nm/emission: 595 nm). Colony forming assay
was performed at the same time as described in the direct
bactericidal assay.
Statistical Analysis
Data are shown as the mean ± SEM. The statistical significance
between means of individual datum points was determined
by one-way analysis of variance (ANOVA) test. Data are
means ± standard deviations from three independent
experiments. A Pvalue of less than 0.05 was regarded as
significant. Correlation between data is indicated in the plots as
the R2 Pearson correlation coefficient.
RESULTS
Screening of PknG Inhibitors by
Luciferase-Based PknG Kinase Assay
To identify PknG inhibitors, we employed a luciferase-based
activity assay that is based on residual ATP levels after PknG-
induced MBP phosphorylation (Koul et al., 2001). We screened
a library of 80 kinase inhibitory compounds (Supplementary
Table S1). The percent inhibition in the approximation curve was
1.058, and the R2 correlation coefficient of the plot was 0.9647.
The experiments were performed twice for each compound
according to the previous protocol reported by Baki et al.
(2007). The two independent experiments showed reproducible
data. Among the active compounds, AZD7762, R406, R406f,
and CYC116 showed a level of inhibition exceeding 50%
relative to the inhibition of PknG by AX20017 (Figure 1A
and Supplementary Table S1), which were used for further
investigation as candidates for anti-mycobacterial agents. The
inhibitory effect was 75.2% by AZD7762, 83.8% by R406,
83.6% by R406f, and 71.2% by CYC116. The IC50 values
of AX20017, AZD7762, R406, R406f, and CYC116 were 5.49,
30.3, 7.98, 16.1, and 35.1 µM, respectively (Figure 1B). These
inhibitors did not show any inhibitory effect on the luciferase
activity at the concentrations used in our assays (Supplementary
Figure S1).
Effect of Kinase Inhibitors on Bacterial
Growth
To analyze the effect of each kinase inhibitor on bacterial
growth, WT BCG, and 1PknG BCG were incubated with serial
FIGURE 1 | Effect of PknG inhibitors on kinase activity and bacterial survival.
(A) Inhibition of PknG by a luciferase-based PknG activity assay. Kinase
inhibition assays were performed using compounds from a kinase inhibitor
library. The kinase reaction was performed using 5 µM of MBP as a substrate,
1 µM of ATP, 1 µM of GST-PknG, and 10 µM of compound per reaction. The
experiment was repeated twice. The initial results were plotted on the
horizontal axis and the second results were on the vertical axis. Correlation
between the data is indicated in the plot as the (R2) Pearson correlation
coefficient. Filled black circle indicates % Inhibition of PknG activity.
(B) Inhibition of GST-PknG activity by different compounds. Kinase inhibitory
assay was performed using fourfold serial dilutions of compounds in the range
from 0.1 to 100 µM. (C) Dose-dependent inhibition of bacterial growth and
metabolism. Mycobacteria were cultured with fourfold serial dilutions of
compounds in the range from 0.03 to 128 µM for 6 days at 37◦C. After the
culture, 20 µL of alamarBlue reagent was added to the culture and incubated
for 4 h at 37◦C. Percent viability of WT (white circle) and 1PknG (filled triangle)
was measured by fluorescence intensity. (D) Effect of kinase inhibitors on
mycobacterial survival. Mycobacterium bovis BCG/Tokyo strain was
incubated at 1 × 105 CFUs/well with 10 µM of each kinase inhibitor at 37◦C
for 24 h. Bacteria were cultured and CFUs were determined after 3–4 weeks.
White rectangle indicates CFU/well. WT: WT BCG, 1PknG: 1PknG BCG,
R406f: R406-free base.
concentrations of the kinase inhibitors. Bacterial growth was
evaluated using alamarBlue reagent. The effect of each kinase
inhibitor on bacterial growth was similar (Figures 1C,D). The
number of CFUs of the BCG treated with 10 µM of each PknG
inhibitor for 24 h at 37◦C was almost identical (Figure 1D).
Phagosome-Lysosome Fusion Analysis
in BCG-Infected Macrophages
To evaluate the consequences of PknG inhibition on phagosome-
lysosome fusion, J774.1 macrophages were infected with GFP-
expressing BCG. After infection, cells were stained with
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FIGURE 2 | Effect of PknG inhibitors on phagocytosis and viability in murine
macrophages. (A) Phagosome-lysosome fusion in BCG-infected
macrophages. J774.1 cells were infected with bacteria at an MOI of 10 for
30 min, then incubated with 10 µM of PknG inhibitors for 90 min. Cells were
fixed, stained with a lysosomal marker, and observed by a confocal laser
scanning microscope. (B) Percentage of lysosomal transfer of WT BCG in the
presence of 10 µM of each inhibitor. One hundred bacteria were counted in
each experiment. The number of transferred bacteria observed for 1PknG
BCG (black bar) was the bacterial number subjected to maximal inhibition
(79%). (C) Phagocytotic activity of murine macrophages treated with each
compound. J774.1 cells were incubated with fourfold serial dilutions of kinase
inhibitors from 0.03 to 128 mM for 2 h. Opsonized beads containing the same
concentration of the test compound were added at an MOI of 10 and
cultured. After 2 h, the fluorescence intensity was measured. (D) Cytotoxicity
of each compound. Serially diluted compound was added to J774.1 cells and
MTT assay was performed after 24 h. The statistical significance between
means of individual datum points was determined by one-way ANOVA test.
∗P < 0.05. WT: WT BCG, 1PknG: 1PknG BCG, control: medium alone,
R406f: R406-free base.
lysosomal LAMP1 antibody. Intracellular BCG was counted
(n = 100) by confocal microscopy. LAMP1 signals overlapping
with GFP signals were regarded as phagosome-lysosome fusion
positive. Fusion between intracellular WT BCG-containing
phagosomes and lysosomes was 31% in the absence of inhibitors.
However, the frequency of fusion increased to about 79%
when cells were infected with 1PknG BCG (Figures 2A,B).
Importantly, after infection of WT BCG, the compounds
AZD7762, R406, and R406f increased the frequency of fusion
between the mycobacteria and lysosomes, whereas CYC116
failed to induce lysosomal delivery of internalized mycobacteria
(Figures 2A,B).
Effect of Novel PknG Inhibitors on
Macrophages
To assess the effect of the identified PknG inhibitors on
macrophages, we examined the phagocytic activity, survival ratio,
and bactericidal activity of macrophages incubated with different
inhibitors (Figures 2, 3).
To analyze phagocytosis, differentiated THP-1 cells were
treated with each PknG inhibitor, and then fluorescent beads
were added to the culture to evaluate the phagocytic ability.
Phagocytic activity was slightly decreased at high concentrations
of AX20017 and R406 and significantly impaired at 8 µM
of R406f and AZD7762 (Figure 3A). We performed the
same experiment using J774.1 cells. A significant reduction of
phagocytic activity was observed for each kinase inhibitor except
AX20017 (Figure 2C).
To examine cytotoxicity of the PknG inhibitors, the survival
ratio of macrophages was measured by MTT assay. No
cytotoxicity was observed on differentiated THP-1 macrophages
treated with R406 or R406f, similar to treatment with AX20017.
However, low levels of cytotoxicity were detected after 24 h
in the presence of AZD7762 (Figure 3B). On the other hand,
cytotoxicity of PknG inhibitors was more strongly observed on
murine J774.1 cells (Figure 2D). Not only AZD7762, but R406
and R406f also showed cytotoxicity at concentrations higher than
2 µM (Figure 2D).
To evaluate bactericidal activity in human macrophages,
differentiated THP-1 cells infected with WT BCG or 1PknG
BCG were incubated with PknG inhibitors. All PknG inhibitors
reduced the growth or metabolic activity of WT BCG in human
macrophages, that was not observed for mycobacteria lacking
PknG, although to a different degree as observed in murine J774.1
macrophages (Walburger et al., 2004). Inhibition of bacterial
growth was assessed by bacterial metabolic activity analysis as
well as colony enumeration (Figures 3C,D). These results showed
that the PknG inhibitors identified by the luciferase-based kinase
assay reduced the growth or survival of BCG in a human
macrophage cell line.
DISCUSSION
Isoniazid, rifampicin, pyrazinamide, and ethambutol have
been used as anti-mycobacterial agents. However, it is very
difficult to eradicate mycobacteria from every infected person,
because existing antibiotics do not have strong potency
against slowly proliferating mycobacteria. Moreover, intracellular
mycobacteria are sequestrated from immune surveillance.
Multidrug-resistant mycobacteria are also emerging. Therefore,
the development of novel anti-mycobacterial drugs is strongly
required.
In this work, compounds exhibiting PknG inhibition were
screened using a luciferase-based PknG kinase assay. The
discovered compounds R406 and R406f promoted fusion
between mycobacteria-containing phagosomes and lysosomes.
Both compounds showed cytotoxicity toward J774.1 cells at the
concentration used for the phagosome-lysosome fusion assay,
and reduced phagocytosis by THP-1 cells at the concentration
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FIGURE 3 | Effect of PknG inhibitors on phagocytosis, cell viability, and
intracellular survival of bacteria in human macrophage. (A) Phagocytotic
activity of differentiated THP-1 cells. Cells were incubated with fourfold serial
dilutions of each compound from 0.03 to 128 mM for 2 h. Opsonized beads
containing the same concentration of the test compound were added at an
MOI of 10 and cultured. The fluorescence intensity was measured after 2 h.
(B) Cytotoxicity of each compound. Serially diluted compound was added to
the differentiated THP-1 cells. MTT assay was performed after 24 h.
(C) Survival of mycobacteria in human macrophage after treatment with PknG
inhibitors. THP-1 macrophages infected with WT BCG or 1PknG BCG were
treated with 10 µM of each compound. After 2 h incubation, infected
macrophages were washed and incubated with amikacin (20 µM) in the
presence of inhibitors. And each compound (10 µM) was added for another
24 h at 37◦C. The macrophages were washed, lysed, and added with 20 µL
of alamarBlue reagent. The mixtures were incubated for 12 h at 37◦C.
Fluorescence intensity of WT BCG (white bar), 1PknG BCG (black bar), and
null (gray bar) infected macrophages were measured. (D) Effect of PknG
inhibitors on survival of mycobacteria in macrophages. Human THP-1
macrophages infected with BCG were treated with 10 µM of each
compound. Infected THP-1 cells were lysed and serially diluted. A total of
10 µl of each diluent were spotted onto an agar plate. After incubation of the
plates, the emerged bacterial colonies were counted. ∗P < 0.05. WT: WT
BCG, 1PknG: 1PknG BCG, control: medium alone, R406f: R406-free base.
used to measure intracellular BCG survival (Figures 2, 3).
Therefore, it is unclear whether these compounds change the
fate of intracellular BCG via their effect on PknG activity or
by their effects on other targets in the macrophages and the
mycobacteria. However, CYC116, the other PknG inhibitor, did
not enhance phagosome-lysosome fusion (Figure 2B). Another
kinase inhibitor, AZD7762, which also inhibits Chk1/2, showed
slight toxicity to macrophages (Figure 3B).
Mycobacterium tuberculosis has 11 serine-threonine protein
kinases: PknA, PknB, PknC, PknD, PknE, PknF, PknG, PknH,
PknJ, PknK, and PknL. These kinases are involved in a number of
processes within M. tuberculosis, including growth, metabolism,
and evasion from lysosomal degradation (Chao et al., 2010).
Inhibitors against PknA and PknB retarded mycobacterial
growth, and inhibitors against PknG suppressed phagosome-
lysosome fusion (Székely et al., 2008). Moreover, sclerotiorin
derived from Penicillium frequentans showed an inhibitory effect
on PknG from M. tuberculosis (Chen et al., 2017). Sclerotiorin
impaired mycobacterial survival in infected macrophages, but
did not show direct inhibition of cultured mycobacterial growth.
However, as happens many times, some compounds cannot
be used on patients because of their side effects. Thus, it still
worthwhile to develop novel compounds that inhibit serine-
threonine protein kinases (Anand et al., 2012; Sipos et al., 2015).
The here used luciferase-based PknG kinase assay is a
powerful tool for screening novel PknG inhibitors. We showed
that R406 enhanced phagosome-lysosome fusion in addition
to PknG inhibition (Figure 2). R406, R406f, and R788
(fostamatinib), a precursor of R406, are Syk kinase inhibitors
(Braselmann et al., 2006; Weinblatt et al., 2010). Because R788 is
already orally administered to patients suffering from rheumatoid
arthritis, it should be possible to develop orally administrable
anti-mycobacterial drugs by selecting drugs more specific to
PknG than to Syk.
We used a modified luciferase based-kinase assay to identify
inhibitors of PknG activity (Baki et al., 2007). Several PknG
inhibitors were recently identified by pharmacophore-based
virtual screening using the crystal structure of PknG (Singh et al.,
2015). Because the amino acid sequence of PknG is identical
between M. bovis BCG and M. tuberculosis, identification of
PknG inhibitors having strong anti-BCG activity may also be
relevant for finding drugs to combat M. tuberculosis. Our
study showed one way to develop drugs targeting mycobacteria
that are difficult to eradicate. However, there are many
differences between mycobacteria in terms of bacterial toxicity
and immunological response against the host. BCG lacks several
genes required for the full pathogenicity of M. tuberculosis (Behr
et al., 1999). The current observations should be pursued with the
use of M. tuberculosis in the near future.
AUTHOR CONTRIBUTIONS
YK, YT, and HY conceived and designed the experiments. YK
and YT performed the experiments. YK, HK, and HI analyzed
the data. HI and YX wrote the manuscript. HT and JP reviewed
the manuscript and supervised the research. All authors read and
approved the final manuscript.
FUNDING
This study was supported by KAKENHI (Grant-in-Aid for
Scientific Research) from the Ministry of Education, Culture,
Sports, Science, and Technology (YK: 18K15168, HI: 18K07147,
Frontiers in Microbiology | www.frontiersin.org 6 July 2018 | Volume 9 | Article 1517
fmicb-09-01517 July 10, 2018 Time: 16:15 # 7
Kanehiro et al. Inhibitors Against Mycobacterial Protein Kinase G
and HY: 16H05843 and 18K07148), GSK Japan Research Grant
2017 (YK), the Swiss National Science Foundation, the UBS
Optimus Foundation, the Cantons of Basel (JP), and the Health
Labor Sciences Research Grant from the Ministry of Health Labor
and Welfare, Japan (HY and HI).
ACKNOWLEDGMENTS
The authors thank Ms. Sayuri Hamada who supported
preparation of the figures.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fmicb.
2018.01517/full#supplementary-material
FIGURE S1 | Effect of different compounds on luciferase activity. Luciferase
activity was examined using 1 µM of ATP, fourfold serial dilutions of compounds in
the range from 0.03 to 128 µM. R406f: R406-free base.
TABLE S1 | Inhibitory activity of each PknG inhibitor by luciferase-based PknG
kinase assay.
REFERENCES
Anand, N., Singh, P., Sharma, A., Tiwari, S., Singh, V., Singh, D. K., et al. (2012).
Synthesis and evaluation of small libraries of triazolylmethoxy chalcones,
flavanones and 2-aminopyrimidines as inhibitors of mycobacterial FAS-II
and PknG. Bioorg. Med. Chem. 20, 5150–5163. doi: 10.1016/j.bmc.2012.
07.009
Armstrong, J. A., and Hart, P. D. (1975). Phagosome-lysosome interactions in
cultured macrophages infected with virulent tubercle bacilli. Reversal of the
usual nonfusion pattern and observations on bacterial survival. J. Exp. Med.
142, 1–16. doi: 10.1084/jem.142.1.1
Baki, A., Bielik, A., Molnár, L., Szendrei, G., and Keserü, G. M. (2007).
A high throughput luminescent assay for glycogen synthase kinase-3
beta inhibitors. Assay Drug Dev. Technol. 5, 75–83. doi: 10.1089/adt.20
06.029
Behr, M. A., Wilson, M. A., Gill, W. P., Salamon, H., Schoolnik, G. K.,
Rane, S., et al. (1999). Comparative genomics of BCG vaccines by whole-
genome DNA microarray. Science 284, 1520–1523. doi: 10.1126/science.284.54
19.1520
Beis, I., and Newsholme, E. A. (1975). The contents of adenine nucleotides,
phosphagens and some glycolytic intermediates in resting muscles from
vertebrates and invertebrates. Biochem. J. 152, 23–32. doi: 10.1042/bj1
520023
Braselmann, S., Taylor, V., Zhao, H., Wang, S., Sylvain, C., Baluom, M., et al. (2006).
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor
signaling and reduces immune complex-mediated inflammation. J. Pharmacol.
Exp. Ther. 319, 998–1008. doi: 10.1124/jpet.106.109058
Chao, J., Wong, D., Zheng, X., Poirier, V., Bach, H., Hmama, Z., et al. (2010).
Protein kinase and phosphatase signaling in Mycobacterium tuberculosis
physiology and pathogenesis. Biochim. Biophys. Acta 1804, 620–627.
doi: 10.1016/j.bbapap.2009.09.008
Chaurasiya, S. K., and Srivastava, K. K. (2009). Downregulation of protein kinase
C-alpha enhances intracellular survival of Mycobacteria: role of PknG. BMC
Microbiol. 9:271. doi: 10.1186/1471-2180-9-271
Chen, D., Ma, S., He, L., Yuan, P., She, Z., and Lu, Y. (2017). Sclerotiorin inhibits
protein kinase G from Mycobacterium tuberculosis and impairs mycobacterial
growth in macrophages. Tuberculosis 103, 37–43. doi: 10.1016/j.tube.2017.
01.001
Chen, J. W., Murphy, T. L., Willingham, M. C., Pastan, I., and August, J. T.
(1985). Identification of two lysosomal membrane glycoproteins. J. Cell Biol.
101, 85–95. doi: 10.1083/jcb.101.1.85
Cooper, J. A. (1987). Effects of cytochalasin and phalloidin on actin. J. Cell Biol.
105, 1473–1478. doi: 10.1083/jcb.105.4.1473
Couldwell, W. T., Hinton, D. R., He, S., Chen, T. C., Sebat, I., Weiss,
M. H., et al. (1994). Protein kinase C inhibitors induce apoptosis in human
malignant glioma cell lines. FEBS Lett. 345, 43–46. doi: 10.1016/0014-5793(94)
00415-3
Cowley, S., Ko, M., Pick, N., Chow, R., Downing, K. J., Gordhan, B. G.,
et al. (2004). The Mycobacterium tuberculosis protein serine/threonine kinase
PknG is linked to cellular glutamate/glutamine levels and is important for
growth in vivo. Mol. Microbiol. 52, 1691–1702. doi: 10.1111/j.1365-2958.2004.
04085.x
Daigneault, M., Preston, J. A., Marriott, H. M., Whyte, M. K., and Dockrell, D. H.
(2010). The identification of markers of macrophage differentiation in PMA-
stimulated THP-1 cells and monocyte-derived macrophages. PLoS One 5:e8668.
doi: 10.1371/journal.pone.0008668
Frieden, T. R., Sterling, T. R., Munsiff, S. S., Watt, C. J., and Dye, C.
(2003). Tuberculosis. Lancet 362, 887–899. doi: 10.1016/S0140-6736(03)
14333-4
Koul, A., Choidas, A., Tyagi, A. K., Drlica, K., Singh, Y., and Ullrich, A. (2001).
Serine/threonine protein kinase PknF and PknG of Mycobacterium tuberculosis:
characterization and localization. Microbiology 147, 2307–2314. doi: 10.1099/
00221287-147-8-2307
Matteelli, A., Roggi, A., and Carvalho, A. C. (2014). Extensively drug-resistant
tuberculosis: epidemiology and management. Clin. Epidemiol. 6, 111–118.
doi: 10.2147/CLEP.S35839
Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J. Immunol. Methods 65,
55–63. doi: 10.1016/0022-1759(83)90303-4
Scherr, N., Honnappa, S., Kunz, G., Mueller, P., Jayachandran, R., Winkler, F.,
et al. (2007). Structural basis for the specific inhibition of protein kinase G, a
virulence factor of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 104,
12151–12156. doi: 10.1073/pnas.0702842104
Singh, N., Tiwari, S., Srivastava, K. K., and Siddiqi, M. I. (2015). Identification
of novel inhibitors of Mycobacterium tuberculosis PknG using pharmacophore
based virtual screening, docking, molecular dynamics simulation, and their
biological evaluation. J. Chem. Inf. Model. 55, 1120–1129. doi: 10.1021/acs.jcim.
5b00150
Sundaramurthy, V., Korf, H., Singla, A., Scherr, N., Nguyen, L., Ferrari, G., et al.
(2017). Survival of Mycobacterium tuberculosis and Mycobacterium bovis BCG
in lysosomes in vivo. Microbes Infect. 19, 515–526. doi: 10.1016/j.micinf.2017.
06.008
Sipos, A., Pató, J., Székely, R., Hartkoorn, R. C., Kékesi, L., Õrfi, L., et al. (2015).
Lead selection and characterization of antitubercular compounds using the
Nested Chemical Library. Tuberculosis 95(Suppl. 1), S200–S206. doi: 10.1016/
j.tube. 2015. 02.02
Smith, D. B., and Johnson, K. S. (1988). Single-step purification
of polypeptides expressed in Escherichia coli as fusions with
glutathione S-transferase. Gene 67, 31–40. doi: 10.1016/0378-1119(88)
90005-4
Székely, R., Wáczek, F., Szabadkai, I., Németh, G., Hegymegi-Barakonyi, B.,
Eros, D., et al. (2008). A novel drug discovery concept for tuberculosis:
inhibition of bacterial and host cell signalling. Immunol. Lett. 116, 225–231.
doi: 10.1016/j.imlet.2007.12.005
Walburger, A., Koul, A., Ferrari, G., Nguyen, L., Prescianotto-Baschong, C.,
Huygen, K., et al. (2004). Protein kinase G from pathogenic Mycobacteria
promotes survival within macrophages. Science 304, 1800–1804. doi: 10.1126/
science.1099384
Wang, S., Midgley, C. A., Scaërou, F., Grabarek, J. B., Griffiths, G., Jackson, W.,
et al. (2010). Discovery of N-phenyl-4-(thiazol-5-yl) primidin-2-amine
aurora kinase inhibitors. J. Med. Chem. 53, 4367–4378. doi: 10.1021/jm
901913s
Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Musser, T. K., Grossbard,
E. B., and Magilavy, D. B. (2010). An oral spleen tyrosine kinase (Syk)
Frontiers in Microbiology | www.frontiersin.org 7 July 2018 | Volume 9 | Article 1517
fmicb-09-01517 July 10, 2018 Time: 16:15 # 8
Kanehiro et al. Inhibitors Against Mycobacterial Protein Kinase G
inhibitor for rheumatoid arthritis. N. Eng. J. Med. 363, 1303–1312. doi: 10.1056/
NEJMoa1000500
Zabludoff, S. D., Deng, C., Grondine, M. R., Sheehy, A. M., Ashwell, S.,
Caleb, B. L., et al. (2008). AZD7762, a novel checkpoint kinase
inhibitor, derives checkpoint abrogation and potentiates DNA-targeted
therapies. Mol. Cancer Ther. 7, 2955–2966. doi: 10.1158/1535-7163.MCT-
08-0492
Zumla, A., George, A., Sharma, V., Herbert, R. H., Baroness Masham of
Ilton, Oxley, A., et al. (2015). The WHO 2014 global tuberculosis report–
further to go. Lancet Glob. Health 3, e10–e12. doi: 10.1016/S2214-109X(14)
70361-4
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Kanehiro, Tomioka, Pieters, Tatano, Kim, Iizasa and Yoshiyama.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 8 July 2018 | Volume 9 | Article 1517
